This is supported by the fact that the use of HDAC inhibition has been shown to exhibit antimyeloma effects through varying modes of action [166], and, as such, the HDAC inhibitor panobinostat is an approved treatment of MM in combination with standard therapies [167]. Here, HDAC9 is linked to Miyoshi myopathy.